# Table of Contents

## Highlights of This Issue 555

### HYPOTHESIS/COMMENTARY

**557** Advances in the Diagnosis and Treatment of Non–Small Cell Lung Cancer  
Rathi N. Pillai and Suresh S. Ramalingam

### SMALL MOLECULE THERAPEUTICS

**565**  
A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo  
Fardokht Abulwerdi, Chenzhong Liao, Meilan Liu, Asfar S. Azmi, Amro Aboutameel, Ahmed S.A. Mady, Thippeswamy Gulappa, Tomasz Cierpicki, Scott Owens, Tao Zhang, Duxin Sun, Jeanne A. Stuckey, Ramzi M. Mohammad, and Zaneta Nikolovska-Coleska

### LARGE MOLECULE THERAPEUTICS

**643** Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity  
Haizhen Wang, Jennifer S. Davis, and Xiangwei Wu

### CANCER BIOLOGY AND SIGNAL TRANSDUCTION

**662** Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism  
Tri K. Nguyen and Steven Grant

**675** XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer  
Yan Cheng, Michael P. Holloway, Kevin Nguyen, Dilara McCauley, Yosef Landesman, Michael G. Kauffman, Sharon Shacham, and Rachel A. Altura

**687** CBP-Mediated FOXO-1 Acetylation Inhibits Pancreatic Tumor Growth by Targeting SirT  
Kartick C. Pramanik, Neel M. Fofaria, Parul Gupta, and Sanjay K. Srivastava
Synuclein γ Compromises Spindle Assembly Checkpoint and Renders Resistance to Antimicrotubule Drugs
Suyu Miao, Kejin Wu, Bo Zhang, Ziyi Weng, Mingjie Zhu, Yunshu Lu, Ramadas Krishna, and Yuenian Eric Shi

Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10–Mediated Paclitaxel Resistance: A Preclinical Study

Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Melanie L. Bailey, Nigel J. O’Neil, Derek M. van Pel, David A. Solomon, Todd Waldman, and Philip Hieter

Mutant Ras Elevates Dependence on Serum Lipids and Creates a Synthetic Lethality for Rapamycin
Darin Salloum, Suman Mukhopadhyay, Kaity Tung, Aleksandra Polonetskaya, and David A. Foster

microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites
Steven M. Offer, Gabriel L. Butterfield, Calvin R. Jerde, Croix C. Fossum, Natalie J. Wegner, and Robert B. Diasio

Cancer-Associated CD43 Glycoforms as Target of Immunotherapy
Franca Maria Tuccillo, Camillo Palmieri, Giuseppe Fiume, Annamaria de Laurentis, Marco Schiavone, Cristina Falcone, Enrico Iaccino, Ricciarda Galandrini, Cristina Capuano, Angela Santoni, Francesco Paolo D’Armiento, Claudio Arra, Antonio Barbieri, Fabrizio Dal Piaz, David Venzon, Patrizia Bonelli, Franco Maria Buonaguro, Iris Scala, Massimo Mallardo, Ileana Quinto, and Giuseppe Scala

Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Letter
Malcolm A. Smith

Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Response
Celine Gongora

STAT3 and NF-κB signaling pathways are often simultaneously activated in neoplastic cells and play important roles in tumorigenesis and drug sensitivity. TPCA-1, a previously found antagonist of IKKs, blocks STAT3 anchoring to upstream tyrosine kinase and inhibits STAT3 activation induced by cytokines and c-Src. Molecular modeling indicates that TPCA-1 is well docked into SH2 domain of STAT3 and formed hydrogen bond with Glu594. As a direct inhibitor of STAT3 and IKKs, TPCA-1 inhibits growth of non–small cell lung cancer (NSCLC) with EGFR mutation and potentiates the antitumor effect of gefitinib. For details, see article by Nan and colleagues on page 617.